


# The MMRF Precision Medicine Model



# MMRF PRECISION MEDICINE MODEL

## THE DATA BANK

Data generation & integration



MMGI  
CoMMpass  
Registry

## THE LEARNING NETWORK

Collaboration and discovery



Gateways  
Myeloma Disease Model  
Translational Network

## THE CLINIC


Accelerating trials



MMRC  
- Molecularly targeted therapies  
- Immune therapies  
- Novel therapies

# MMRF COMMPASS STUDY AS CORNERSTONE

## Longitudinal Clinical Data and Molecular Profiling



**TARGET ENROLLMENT:** 1,000 newly diagnosed patients

**DURATION:** ~10 years

**SITES:** ~90 Community and Academic Centers (4 countries)


**INDUSTRY PARTNERS:** Takeda, Amgen, Janssen, BMS

---

## Centralized Molecular Tests


- Flow cytometry & BRAF mutations
- RNA sequencing expression analysis
- Whole exome DNA sequencing
- Whole genome chromosome analysis
- Cytospin slides for FISH
- Biorespository of PBMNC, plasma Tumor

# BRAF: DISCOVERY TO CLINIC




# ACTIONABLE TARGETS

50 percent of patients with multiple myeloma have known molecular alterations for which there are drugs on the market or in the clinic.




# MM MASTER PROTOCOL

## Genomic profiling for alterations



# THE DATA BANK

Data generation & integration



MMGI  
CoMMpass  
Registry

# THE LEARNING NETWORK

Collaboration and discovery



Gateways  
Myeloma Disease Model  
Translational Network

# THE CLINIC

Accelerating trials



MMRC  
- Molecularly targeted therapies  
- Immune therapies  
- Novel therapies

# THE PATIENT

